TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) – Equities research analysts at HC Wainwright lifted their Q4 2026 earnings per share (EPS) estimates for TG Therapeutics in a research note issued on Monday, August 3rd. HC Wainwright also issued estimates for TG Therapeutics’ FY2028 earnings at $3.58 EPS, FY2029 earnings at $4.53 EPS and FY2030 earnings at $5.64 EPS. Get TG Therapeutics alerts:TG Therapeutics (NASDAQ:TGTX – Get Free Report) last posted its earnings results on Monday, August 3rd. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology. In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.Further ReadingReceive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.